2 unknown, 1 terminated. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 1, Unknown 1 |
| Phase 1 | 1 | Unknown 1 |
Follow EOM613: new trials by email Literature Review of EOM613 trials Research Report on EOM613
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Proof-of-Concept Study Evaluating EOM613 in COVID-19 Infected Patients With Severe Symptoms EOM613 - COVID-19 Pneumonia, COVID-19 Respiratory Infection | Phase 1 | Unknown | EOM Pharmaceuticals | 40 | 2021-08-09 | 2022-01-28 |
| Open Label Study With OHR/AVR118 in Advanced Cancer Patients With Anorexia-Cachexia OHR/AVR118 - Anorexia, Cancer Cachexia | Phase 2 | Unknown | Ohr Pharmaceutical Inc. | 20 | 2010-09-01 | 2012-11-27 |
| A Phase II Open Label, Multi-Center Study With AVR118 in Anorectic Patients With Recurrent or Advanced Malignancies AVR118 - Cancer | Phase 2 | Terminated | McGill University | 30 | 2007-10-01 | 2019-03-14 |
Anorexia (1) · COVID-19 (1) · Fatigue (1) · Neoplasms (1) · Weight Loss (1)
EOM Pharmaceuticals (1) · McGill University (1) · Ohr Pharmaceutical Inc. (1)
Canada (2) · Brazil (1)
Florentino Cardoso Filho, MD, PhD (1) · Frank L Douglas, PhD, MD (1) · Irach Taraporewala, PhD (1) · Maribel de Diego, Ph.D. (1) · Martin Chasen, MBChB (1)